Navigation Links
American Oriental Bioengineering Announces Participation in November Investor Conferences
Date:10/31/2008

NEW YORK, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOBO"), a leading marketer, distributor and manufacturer of pharmaceutical and healthcare products in China, today announced that the Company will present at the following conferences:

-- Oppenheimer 19th Annual Healthcare Conference, held at the Waldorf-

Astoria in New York. Management is currently scheduled to present at

8:40 am ET on Tuesday, November 4, 2008.

-- Credit Suisse Asia Healthcare Conference, held at the Westin in Beijing.

Management is currently scheduled to present at 4:30 pm local time on

Wednesday, November 5, 2008;

-- Morgan Stanley 2008 Asia Pacific Summit, held at the Mandarin Oriental

in Singapore. Management is currently scheduled to present at 3:15 pm

local time on Wednesday, November 12, 2008;

-- Oppenheimer 4th Annual 'Best Ideas' Conference, held at the Millennium

Broadway in New York. Management is currently scheduled to present at

1:20 pm ET on Tuesday, November 18, 2008. A webcast of this

presentation will be available via the Company's website at

http://www.bioaobo.com .

-- Lazard 5th Annual Healthcare Conference, held at the St. Regis in New

York. Management is currently scheduled to present at 11:30 am ET on

Wednesday, November 19, 2008.

For more details on the conferences, please contact your respective institutional sales representative.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Basel, Switzerland (PRWEB) , ... May 23, 2017 ... ... for R&D, celebrates this month its 20th anniversary, marking the occasion with a ... is sponsoring the meeting’s Welcome Reception and further extends an invitation to all ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ... the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Bacterial biofilms, surface ... molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum ... is in the tens of billions of dollars per year, there is currently a ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Stratevi, a ... expanded to the East Coast. It has opened an office in downtown Boston at ... are finding it increasingly more important to generate evidence on the value they provide, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):